[go: up one dir, main page]

MX2017011281A - Conjugados de amatoxina y anticuerpos. - Google Patents

Conjugados de amatoxina y anticuerpos.

Info

Publication number
MX2017011281A
MX2017011281A MX2017011281A MX2017011281A MX2017011281A MX 2017011281 A MX2017011281 A MX 2017011281A MX 2017011281 A MX2017011281 A MX 2017011281A MX 2017011281 A MX2017011281 A MX 2017011281A MX 2017011281 A MX2017011281 A MX 2017011281A
Authority
MX
Mexico
Prior art keywords
amatoxin
antibody conjugates
amatoxins
conjugates
antibodies
Prior art date
Application number
MX2017011281A
Other languages
English (en)
Other versions
MX391989B (es
Inventor
Mueller Christoph
Anderl Jan
Pahl Andreas
Hechler Torsten
Original Assignee
Heidelberg Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Gmbh filed Critical Heidelberg Pharma Gmbh
Publication of MX2017011281A publication Critical patent/MX2017011281A/es
Publication of MX391989B publication Critical patent/MX391989B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invención se refiere a conjugados que comprenden amatoxinas y anticuerpos, en particular amatoxinas ligadas a anticuerpos que comprenden residuos de cisteína específicos.
MX2017011281A 2015-03-09 2016-03-07 Conjugados de amatoxina y anticuerpos. MX391989B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15000681 2015-03-09
PCT/EP2016/000397 WO2016142049A1 (en) 2015-03-09 2016-03-07 Amatoxin-antibody conjugates

Publications (2)

Publication Number Publication Date
MX2017011281A true MX2017011281A (es) 2018-05-15
MX391989B MX391989B (es) 2025-03-21

Family

ID=52648788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011281A MX391989B (es) 2015-03-09 2016-03-07 Conjugados de amatoxina y anticuerpos.

Country Status (25)

Country Link
US (1) US10842882B2 (es)
EP (2) EP4115910A1 (es)
JP (2) JP6863900B2 (es)
KR (1) KR102777899B1 (es)
CN (2) CN114395050B (es)
AU (1) AU2016228415B2 (es)
BR (1) BR112017019300B1 (es)
CA (1) CA2978064A1 (es)
DK (1) DK3268047T3 (es)
ES (1) ES2968012T3 (es)
FI (1) FI3268047T3 (es)
HR (1) HRP20240075T1 (es)
HU (1) HUE064698T2 (es)
IL (2) IL254108B (es)
LT (1) LT3268047T (es)
MX (1) MX391989B (es)
NZ (1) NZ734892A (es)
PL (1) PL3268047T3 (es)
PT (1) PT3268047T (es)
RS (1) RS64955B1 (es)
RU (1) RU2724328C2 (es)
SG (2) SG11201707054PA (es)
SI (1) SI3268047T1 (es)
WO (1) WO2016142049A1 (es)
ZA (1) ZA201705770B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016071856A1 (en) 2014-11-06 2016-05-12 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
WO2016142049A1 (en) * 2015-03-09 2016-09-15 Heidelberg Pharma Gmbh Amatoxin-antibody conjugates
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
CN109641051A (zh) 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
WO2017219029A2 (en) 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+cells
HRP20241686T1 (hr) 2016-12-23 2025-02-14 Heidelberg Pharma Research Gmbh Konjugati amanitina s protutijelom
KR102725761B1 (ko) 2017-01-20 2024-11-04 하이델베르크 파마 리서치 게엠베하 Cd137+ 세포의 고갈을 위한 조성물 및 방법
US10961277B2 (en) * 2017-08-07 2021-03-30 Heidelberg Pharma Research Gmbh Method for synthesizing amanitins
WO2019034175A1 (zh) * 2017-08-18 2019-02-21 四川百利药业有限责任公司 一种非天然鹅膏毒肽类抗体偶联物
WO2019047941A1 (zh) * 2017-09-08 2019-03-14 四川百利药业有限责任公司 鹅膏毒肽类抗体偶联物
WO2019057964A1 (en) * 2017-09-22 2019-03-28 Heidelberg Pharma Research Gmbh AMANITINE CONJUGATES TARGETING PSMA
SG11202003280SA (en) * 2017-10-24 2020-05-28 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+ cells
CA3079215A1 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
IL316155A (en) 2017-11-29 2024-12-01 Heidelberg Pharma Res Compositions and Methods for the Depletion of CD5(PLUS) CELLS
KR20200099123A (ko) 2017-12-15 2020-08-21 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 생체활성 접합체, 이의 제조 방법 및 용도
EP3773740A1 (en) 2018-04-13 2021-02-17 Heidelberg Pharma Research GmbH Targeted amatoxin conjugate for the treatment of solid tumors
CA3107019A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy
AU2019366960A1 (en) * 2018-10-23 2021-05-27 Regeneron Pharmaceuticals, Inc. Fc silenced antibody drug conjugates (ADCs) and uses thereof
CN113874051A (zh) * 2019-02-27 2021-12-31 安吉克公司 包含抗tm4sf1抗体的抗体-药物缀合物及其使用方法
AU2020263959B2 (en) * 2019-04-24 2026-01-22 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
AU2020278178B2 (en) 2019-05-23 2026-01-22 Heidelberg Pharma Research Gmbh Antibody drug conjugates with cleavable linkers
JP2022535527A (ja) * 2019-06-04 2022-08-09 マジェンタ セラピューティクス インコーポレイテッド 自己免疫疾患を治療するための方法および組成物
AU2020286508A1 (en) * 2019-06-05 2022-01-06 Heidelberg Pharma Research Gmbh T-cell depleting therapies
AR120218A1 (es) * 2019-10-15 2022-02-02 Heidelberg Pharma Res Gmbh Conjugados de amatoxina y anticuerpo específico de linfocitos b
CN111308100B (zh) * 2020-04-13 2023-04-21 北京维德维康生物技术有限公司 一种检测β-鹅膏毒肽的酶联免疫试剂盒及其制备和应用
WO2021250059A1 (en) 2020-06-09 2021-12-16 Heidelberg Pharma Research Gmbh Method for synthesis of thioether-containing peptides
WO2021255217A1 (en) 2020-06-19 2021-12-23 Heidelberg Pharma Research Gmbh Amatoxin and amatoxin conjugates for use in inhibition of rna virus replication
CA3195572A1 (en) 2020-11-04 2022-05-12 Heidelberg Pharma Research Gmbh Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy
WO2022194988A2 (en) 2021-03-19 2022-09-22 Heidelberg Pharma Research Gmbh B-lymphocyte specific amatoxin antibody conjugates
TWI895608B (zh) * 2021-04-29 2025-09-01 愛爾蘭商艾伯維製造管理無限公司 抗c-Met抗體藥物結合物
JP2024517872A (ja) 2021-05-03 2024-04-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ＨＥＲ２を標的にするＦｃ抗原結合性フラグメント－薬物抱合体
CN113980909B (zh) * 2021-11-16 2022-06-14 江南大学 一种α-鹅膏蕈碱人工抗原、单克隆抗体、杂交瘤细胞株及应用
EP4504270A1 (en) 2022-04-07 2025-02-12 Heidelberg Pharma Research GmbH Methods of improving the therapeutic index of amatoxin-antibody conjugates
TW202412843A (zh) 2022-08-10 2024-04-01 日商興和股份有限公司 新藥物複合體
TW202421207A (zh) 2022-09-30 2024-06-01 大陸商上海迪諾醫藥科技有限公司 苯并氮雜卓衍生物、含其的偶聯物及其應用
EP4611897A1 (en) 2022-11-01 2025-09-10 Heidelberg Pharma Research GmbH Anti-gucy2c antibody and uses thereof
EP4680285A1 (en) 2023-03-13 2026-01-21 Heidelberg Pharma Research GmbH Subcutaneously administered antibody-drug conjugates for use in cancer treatment
CN120957753A (zh) 2023-03-23 2025-11-14 广州百济神州生物制药有限公司 生物活性结合物、其制备方法和其用途
WO2025109097A2 (en) 2023-11-24 2025-05-30 Heidelberg Pharma Research Gmbh Novel nicotinamide phosphoribosyltransferase inhibitors and uses thereof
EP4566631A1 (en) 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
ATE521366T1 (de) 2006-05-27 2011-09-15 Faulstich Heinz Dr Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
ES2523915T5 (es) * 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
MX2011010469A (es) 2009-04-08 2012-03-14 Deutsches Krebsforsch Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer.
CA2758201C (en) 2009-04-08 2017-08-01 Deutsches Krebsforschungszentrum Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
ES2402254T3 (es) * 2010-09-30 2013-04-30 Heidelberg Pharma Ag Conjugados de amatoxinas con ligadores mejorados
US20150218220A1 (en) * 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
EP2774624A1 (en) * 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
KR102057755B1 (ko) 2013-03-13 2019-12-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
CN105636612B (zh) 2013-08-12 2020-01-14 基因泰克公司 抗体-药物缀合物及使用和治疗方法
WO2015123265A1 (en) * 2014-02-11 2015-08-20 Seattle Genetics, Inc. Selective reduction of proteins
WO2016071856A1 (en) * 2014-11-06 2016-05-12 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
WO2016142049A1 (en) * 2015-03-09 2016-09-15 Heidelberg Pharma Gmbh Amatoxin-antibody conjugates
AU2019426942B2 (en) * 2019-01-31 2023-11-16 Hangzhou Dac Biotech Co., Ltd A conjugate of an amanita toxin with branched linkers
AU2020263959B2 (en) * 2019-04-24 2026-01-22 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof

Also Published As

Publication number Publication date
BR112017019300B1 (pt) 2023-02-23
US10842882B2 (en) 2020-11-24
ES2968012T3 (es) 2024-05-06
JP6863900B2 (ja) 2021-04-21
KR20180003537A (ko) 2018-01-09
EP3268047B9 (en) 2024-01-10
EP4115910A1 (en) 2023-01-11
LT3268047T (lt) 2023-11-10
RS64955B1 (sr) 2024-01-31
KR102777899B1 (ko) 2025-03-06
SG11201707054PA (en) 2017-09-28
IL254108B (en) 2021-09-30
EP3268047B1 (en) 2023-10-18
CN114395050B (zh) 2025-03-14
RU2017132185A3 (es) 2019-05-23
CN114395050A (zh) 2022-04-26
AU2016228415B2 (en) 2021-04-01
HRP20240075T1 (hr) 2024-03-29
WO2016142049A1 (en) 2016-09-15
IL285516A (en) 2021-09-30
MX391989B (es) 2025-03-21
PT3268047T (pt) 2023-12-05
RU2017132185A (ru) 2019-04-09
DK3268047T3 (da) 2024-01-02
IL254108A0 (en) 2017-10-31
JP2018513120A (ja) 2018-05-24
US20180043033A1 (en) 2018-02-15
HUE064698T2 (hu) 2024-04-28
EP3268047A1 (en) 2018-01-17
CN107636016B (zh) 2022-02-11
CA2978064A1 (en) 2016-09-15
NZ734892A (en) 2023-03-31
FI3268047T3 (fi) 2023-12-21
PL3268047T3 (pl) 2024-03-18
CN107636016A (zh) 2018-01-26
IL285516B (en) 2022-04-01
SG10201913963RA (en) 2020-03-30
BR112017019300A2 (pt) 2018-05-08
JP7083935B2 (ja) 2022-06-13
NZ773646A (en) 2024-05-31
RU2724328C2 (ru) 2020-06-23
ZA201705770B (en) 2022-02-23
SI3268047T1 (sl) 2024-02-29
JP2021100974A (ja) 2021-07-08
AU2016228415A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
MX2017011281A (es) Conjugados de amatoxina y anticuerpos.
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CO2019005966A2 (es) Esteroides y conjugados de proteínas de los mismos
CO2018005436A2 (es) Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica
CL2018000920A1 (es) Conjugados de anticuerpos que comprenden agonistas de receptor similares
BR112018001955A2 (pt) anticorpos monoclonais contra bcma
ECSP18000844A (es) Anticuerpos de unión a tau
MA49034A (fr) Anticorps anti-lag3
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EP3397276A4 (en) ANTIBODIES AND CONJUGATES THEREOF
IL256271B (en) Anti-cd123 antibodies and conjugates and derivatives thereof
SI3347379T1 (sl) ANTI-TIGIT protitelesa, ANTI-PVRIG protitelesa in njihove kombinacije
HUE056289T2 (hu) Pirrolobenzodiazepin-antitest konjugátumok
EP3307274A4 (en) CD123 ANTIBODIES AND CONJUGATES THEREOF
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112015032224A2 (pt) anticorpos anti-fcrh5
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
ECSP18000887A (es) Anticuerpos de unión a tau
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
DK3544636T3 (da) Pyrrolobenzodiazepin-antistof-konjugater
HUE054037T2 (hu) CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra
EP3617231A4 (en) ANTI-GPC-1 ANTIBODY
GB201614162D0 (en) Antibodies, uses thereof and conjugates thereof
EP3692072A4 (en) ANTI-HLA-DQ2.5 ANTIBODIES